163 related articles for article (PubMed ID: 27247756)
21. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
22. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
23. The Syk kinase as a therapeutic target in leukemia and lymphoma.
Efremov DG; Laurenti L
Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
[TBL] [Abstract][Full Text] [Related]
24. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
[TBL] [Abstract][Full Text] [Related]
25. The B-cell receptor pathway: a critical component of healthy and malignant immune biology.
Zhong Y; Byrd JC; Dubovsky JA
Semin Hematol; 2014 Jul; 51(3):206-18. PubMed ID: 25048784
[TBL] [Abstract][Full Text] [Related]
26. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Awan FT; Thirman MJ; Patel-Donnelly D; Assouline S; Rao AV; Ye W; Hill B; Sharman JP
Leuk Lymphoma; 2019 Aug; 60(8):1972-1977. PubMed ID: 30633573
[TBL] [Abstract][Full Text] [Related]
27. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
[TBL] [Abstract][Full Text] [Related]
28. B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292.
Arnason JE; Brown JR
Immunotargets Ther; 2014; 3():29-38. PubMed ID: 27471698
[TBL] [Abstract][Full Text] [Related]
29. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.
Madanat YF; Smith MR; Almasan A; Hill BT
Blood Lymphat Cancer; 2016; 6():1-6. PubMed ID: 27375364
[TBL] [Abstract][Full Text] [Related]
30. Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
Kakodkar P; More S; András K; Papakonstantinou N; Kelly S; Makrooni MA; Ortutay C; Szegezdi E
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664705
[TBL] [Abstract][Full Text] [Related]
31. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
Puri KD; Di Paolo JA; Gold MR
Int Rev Immunol; 2013 Aug; 32(4):397-427. PubMed ID: 23886342
[TBL] [Abstract][Full Text] [Related]
32. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
33. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
34. [Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future].
Špaček M
Klin Onkol; 2015; 28 Suppl 3():3S45-9. PubMed ID: 26489501
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T; Robak E
Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
[TBL] [Abstract][Full Text] [Related]
36. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
37. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
[TBL] [Abstract][Full Text] [Related]
38. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
39. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
[TBL] [Abstract][Full Text] [Related]
40. Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Sana I; Mantione ME; Angelillo P; Muzio M
Front Oncol; 2021; 11():651057. PubMed ID: 33869054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
